Caribou Biosciences (NASDAQ:CRBU) Shares Gap Up to $10.02

Caribou Biosciences, Inc. (NASDAQ:CRBUGet Rating) gapped up prior to trading on Tuesday . The stock had previously closed at $10.02, but opened at $10.32. Caribou Biosciences shares last traded at $10.03, with a volume of 1,757 shares.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CRBU. Citigroup lifted their price objective on Caribou Biosciences from $29.00 to $39.00 in a research report on Thursday, May 12th. SVB Leerink boosted their price objective on shares of Caribou Biosciences from $30.00 to $34.00 in a report on Thursday, May 12th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Caribou Biosciences has an average rating of “Buy” and a consensus price target of $29.71.

Caribou Biosciences Price Performance

The stock’s 50-day moving average is $7.11 and its two-hundred day moving average is $8.37.

Hedge Funds Weigh In On Caribou Biosciences

A number of institutional investors have recently modified their holdings of CRBU. Ameritas Investment Partners Inc. boosted its stake in Caribou Biosciences by 168.4% in the first quarter. Ameritas Investment Partners Inc. now owns 3,945 shares of the company’s stock valued at $36,000 after acquiring an additional 2,475 shares in the last quarter. Amalgamated Bank purchased a new position in shares of Caribou Biosciences during the first quarter worth $45,000. Penserra Capital Management LLC purchased a new stake in shares of Caribou Biosciences during the 1st quarter worth about $61,000. Virtus ETF Advisers LLC purchased a new position in shares of Caribou Biosciences in the 4th quarter valued at about $150,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Caribou Biosciences in the 2nd quarter valued at about $57,000. 62.86% of the stock is owned by hedge funds and other institutional investors.

Caribou Biosciences Company Profile

(Get Rating)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma.

Read More

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Caribou Biosciences (NASDAQ:CRBU) Shares Gap Up to $10.02

Caribou Biosciences, Inc. (NASDAQ:CRBUGet Rating)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $10.02, but opened at $10.32. Caribou Biosciences shares last traded at $10.03, with a volume of 1,757 shares.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. SVB Leerink lifted their price target on shares of Caribou Biosciences from $30.00 to $34.00 in a report on Thursday, May 12th. Citigroup boosted their target price on shares of Caribou Biosciences from $29.00 to $39.00 in a research report on Thursday, May 12th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Caribou Biosciences currently has a consensus rating of “Buy” and an average target price of $29.71.

Caribou Biosciences Price Performance

The business has a 50-day moving average price of $7.11 and a 200 day moving average price of $8.37.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC purchased a new stake in Caribou Biosciences in the 4th quarter worth about $334,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Caribou Biosciences during the fourth quarter worth $321,000. New York State Common Retirement Fund increased its stake in shares of Caribou Biosciences by 23.5% in the 4th quarter. New York State Common Retirement Fund now owns 21,447 shares of the company’s stock valued at $324,000 after purchasing an additional 4,086 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. purchased a new position in shares of Caribou Biosciences in the 4th quarter valued at about $213,000. Finally, Monashee Investment Management LLC boosted its holdings in shares of Caribou Biosciences by 12.2% during the 4th quarter. Monashee Investment Management LLC now owns 504,377 shares of the company’s stock worth $7,611,000 after purchasing an additional 55,000 shares during the last quarter. Institutional investors own 62.86% of the company’s stock.

Caribou Biosciences Company Profile

(Get Rating)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma.

Read More

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.